ABSTRACT
Adverse cutaneous reactions associated with the immune checkpoint inhibitor (ICI) pembrolizumab are well documented, yet life-threatening reactions such as Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) are infrequent.1,2 We present a case of pembrolizumab-induced TEN in a patient with metastatic esophageal adenocarcinoma who was successfully treated with cyclosporine and systemic corticosteroids.
Subject(s)
Adenocarcinoma , Stevens-Johnson Syndrome , Adenocarcinoma/drug therapy , Antibodies, Monoclonal, Humanized/adverse effects , Humans , Skin , Stevens-Johnson Syndrome/etiology , Stevens-Johnson Syndrome/therapySubject(s)
Erythema Chronicum Migrans , Glossitis, Benign Migratory , Syphilis , Cellulitis/diagnosis , HumansABSTRACT
We present two infants with histologically confirmed congenital dermatomyofibromas. Congenital cases are rare with only one prior case reporting presence since birth. Given the benign nature of the lesions and propensity of dermatomyofibromas to resolve without intervention in young male patients, no additional treatments were pursued.
